Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...

Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022.

Baird analyst David Rescott lowered the firm’s price target on TransMedics (TMDX) to $120 from $150 and keeps an Outperform rating on the shares. The firm said at the company’s inaugural ...

JPMorgan analyst Allen Gong downgraded TransMedics (TMDX) to Neutral from Overweight with a price target of $75, down from $116. The company’s near-term outlook “remains less certain” as ...